Axicabtagene ciloleucel

From Ganfyd

Revision as of 10:51, 31 December 2017 by Mlj (Talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Axicabtagene ciloleucel is chimeric antigen receptor T-cell immunotherapy (CAR-T cell therapy) preparation of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19. The product is in development to treat adult patients with non-Hodgkin lymphoma (NHL), diffuse large B cell lymphoma (DLBCL)[1], primary mediastinal B-cell lymphoma (PMBCL), transformed follicular lymphoma (TFL)[2], chronic lymphocytic leukaemia and acute lymphoblastic leukaemia (ALL)[3]. It is a member of the EMEA's PRIority MEdicines (PRIME) scheme for breakthrough therapies. Licensing commenced in major markets 2017/18.